DEF: Silo Pharma: 2025 Annual Meeting, Reverse Split Proposed

Silo Pharma, Inc. announces its 2025 Annual Meeting of Shareholders to vote on director elections, auditor ratification, a reverse stock split, and an equity plan amendment.

Summary

• The 2025 Annual Meeting of Shareholders for Silo Pharma, Inc. is scheduled for October 24, 2025, at 11:00 a.m. Eastern Time in Sarasota, Florida.
• Shareholders will vote on five key proposals: the election of four directors, ratification of Salberg & Company, P.A. as the independent auditor for fiscal year 2025, approval of a reverse stock split, approval of an amendment to the 2020 Omnibus Equity Incentive Plan, and authorization for adjournment.
• The proposed reverse stock split ratio is within the range of 1-for-2 to 1-for-20, with the final ratio to be determined by the board within one year of approval.
• The company received a Nasdaq notice on June 27, 2025, for non-compliance with the $1.00 minimum bid price requirement, with a deadline of December 24, 2025, to regain compliance.
• The proposed amendment to the Equity Incentive Plan seeks to increase the share reserve by 930,000 shares, bringing the total available for grant to 1,400,000 shares, and adds an evergreen provision for annual increases.
• As of the record date, August 25, 2025, there were 9,461,128 shares of common stock outstanding, and the closing price was $0.64 per share.
• The Board of Directors unanimously recommends voting FOR all proposals.

Sentiment

Score: 4

Explanation: The filing outlines necessary corporate actions to maintain Nasdaq listing and incentivize personnel, which are positive for operational continuity. However, the underlying reasons for these actions (sub-$1.00 share price, consistent losses, and significant potential dilution from the equity plan) indicate ongoing challenges and a need for substantial future growth to justify current valuations.

Positives

• The Board of Directors is comprised of four directors, with three identified as independent, reinforcing board independence in oversight.
• Established Audit, Compensation, and Nominating and Corporate Governance Committees are in place, all with independent members, ensuring structured oversight.
• Wayne D. Linsley, a member of the Audit Committee, qualifies as an audit committee financial expert, enhancing financial oversight capabilities.
• The company has adopted a written Code of Business Conduct and Ethics and an Insider Trading Policy, including anti-hedging provisions, promoting ethical conduct and compliance.
• Directors, executive officers, and greater than 10% beneficial owners complied with Section 16(a) filing requirements for the fiscal year ended December 31, 2024.
• The proposed Equity Plan Amendment aims to attract and retain superior talent, strengthen commitment, and motivate individuals to contribute to the company's long-term growth and profitability.
• The company asserts responsible use of equity and good corporate governance practices, stating the expanded equity plan provides a platform for continued growth while managing costs and share utilization within acceptable industry standards.

Negatives

• The company is not in compliance with Nasdaq's $1.00 minimum bid price requirement, having received a notice on June 27, 2025, with a deadline of December 24, 2025, to regain compliance.
• The proposed reverse stock split (1-for-2 to 1-for-20) is primarily a reactive measure to address the low share price and maintain Nasdaq listing, which can be perceived negatively by investors.
• The reverse stock split will effectively increase the number of authorized but unissued shares, creating potential for future dilution for existing shareholders.
• The proposed Equity Plan Amendment significantly increases the share reserve by 930,000 shares and includes an evergreen provision, leading to a potential dilution of approximately 12.84% of fully diluted shares as of August 25, 2025.
• The company reported consistent net losses for the past three fiscal years: $(4,392,880) in 2024, $(3,700,683) in 2023, and $(3,908,551) in 2022.

Risks

• Failure to regain compliance with Nasdaq's $1.00 minimum bid price requirement could lead to delisting, which would significantly reduce the trading market liquidity and potentially the trading price of common stock.
• The post-split market price of common stock may not be proportional to the pre-split price multiplied by the reverse stock split ratio, and a reduction in outstanding shares may impair liquidity.
• Future issuance of additional shares, made possible by the effective increase in authorized shares post-reverse split and the expanded equity plan, could have a dilutive effect on earnings per share, book value per share, and shareholder voting rights.
• The issuance of authorized but unissued shares could be used to deter potential takeovers, which might otherwise be beneficial to shareholders by offering a premium for their shares.
• The U.S. federal income tax consequences of receiving a whole share in lieu of a fractional share due to rounding up are not clear and may result in income or gain for U.S. Holders.

Future Outlook

The company intends to effect a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and improve the trading price of its common stock. The effective increase in authorized and unissued shares post-split, along with the expanded equity incentive plan, is intended to provide flexibility for future financing opportunities, mergers and acquisitions, strategic collaborations, and equity incentives for employees, officers, directors, and consultants to support long-term growth and profitability.

Management Comments

• Our Board unanimously recommends that you vote FOR the election of our Boards director nominees (Proposal 1); FOR the ratification of the appointment of Salberg as our independent registered public accounting firm for the fiscal year ending December 31, 2025 (Proposal 2); FOR the Reverse Split Proposal (Proposal 3); FOR the Equity Plan Amendment Proposal (Proposal 4); and FOR the approval of the Adjournment Proposal (Proposal 5).
• We believe that enabling the board of directors to fix the specific ratio of the Reverse Stock Split within the stated range will provide us with the flexibility to implement it in a manner designed to maximize the anticipated benefits for our shareholders.
• Our Board intends to effect the Reverse Stock Split only if it believes that a decrease in the number of shares outstanding is in the best interests of the Company and our shareholders and is likely to improve the trading price of our Common Stock and improve the likelihood that we will be allowed to maintain our listing on Nasdaq.
• The Board believes that this number of shares of common stock constitutes reasonable potential equity dilution and provides a significant incentive for employees and service providers to increase the value of the Company for all shareholders.
• As exhibited by our responsible use of equity over the past several years and good corporate governance practices associated with equity and executive compensation practices in general, the stock reserved under the Amended and Restated 2020 Plan will provide us with the platform needed for our continued growth, while managing program costs and share utilization levels within acceptable industry standards.

Industry Context

The proposed reverse stock split is a common measure taken by companies, particularly in the biotechnology or early-stage pharmaceutical sectors, to maintain listing on major exchanges like Nasdaq when their share price falls below minimum requirements. Maintaining Nasdaq listing is crucial for visibility, liquidity, and access to capital, which are vital for companies in R&D-intensive industries. The expansion of the equity incentive plan is also typical for growth-oriented companies seeking to attract and retain talent in competitive fields, especially those with a scientific advisory board focused on neuropsychiatric disorders and psilocybin therapy.

Comparison to Industry Standards

• The company's need for a reverse stock split due to a sub-$1.00 share price is a common challenge for smaller, often pre-revenue or early-stage, biotech companies. Many peers in the micro-cap biotech space, such as Cassava Sciences (SAVA) or Athersys (ATHX) during periods of low share prices, have faced similar listing compliance issues and have either considered or executed reverse stock splits.
• The proposed equity incentive plan, with an initial 1,400,000 shares and an evergreen provision of up to 5% of outstanding shares annually (capped at 1,400,000 shares per year for ISOs), represents a significant potential dilution (12.84% fully diluted). While equity compensation is standard in biotech to attract talent, this level of potential dilution should be compared to industry averages for similar-stage companies, where typical ranges for equity compensation plans might be 10-15% of outstanding shares, but evergreen provisions can lead to higher ongoing dilution.
• The company's consistent net losses (e.g., $(4.39) million in 2024) are typical for early-stage pharmaceutical companies heavily invested in research and development, where significant revenue generation is often years away. This contrasts with established pharmaceutical companies like Pfizer (PFE) or Johnson & Johnson (JNJ), which generate substantial profits.

Management Changes

Corporate Governance

Legal Proceedings

• No material proceedings exist in which any directors or executive officers are adverse parties to the company or have a material adverse interest.
• No awareness of any directors or officers being involved in any legal proceedings in the past ten years relating to bankruptcy, insolvency, or criminal proceedings (other than traffic and other minor offenses).

Related Party Transactions

• No transactions exceeding the lesser of $120,000 or 1% of average total assets were reported for fiscal years ended December 31, 2025, and 2024, other than equity and other compensation arrangements described elsewhere in the filing.
• Members of the Board and executive officers have a direct interest in Proposal 1 (election of directors) and Proposal 4 (Equity Plan Amendment) as it relates to a compensatory plan in which they participate.

Stakeholder Impact

• **Shareholders**: Will experience a reduction in the number of shares held and an increase in per-share price if the reverse stock split is approved and implemented. Potential for future dilution from the increased share reserve in the equity plan. Voting power percentage will remain the same, but fractional shares will be rounded up.
• **Employees, Officers, Directors, and Consultants**: Will benefit from the expanded equity incentive plan, which aims to attract, retain, and motivate them through stock-based awards, aligning their interests with company performance.
• **Nasdaq**: The reverse stock split is intended to ensure continued listing compliance, benefiting the company's standing on the exchange and maintaining its access to broader capital markets.
• **Investment Professionals**: The reverse stock split may make the stock more attractive to institutional investors who have internal policies against investing in low-priced stocks, potentially enhancing liquidity and broadening the investor base.

Next Steps

• Shareholders are to vote on the proposals at the 2025 Annual Meeting on October 24, 2025.
• If approved, the Board of Directors will determine the specific ratio for the reverse stock split (between 1-for-2 and 1-for-20) and the timing of its implementation within one year of approval.
• If the reverse stock split is effected, the company will file an amendment to its Articles of Incorporation with the Secretary of State of Nevada.
• The company must regain compliance with Nasdaq's $1.00 minimum bid price requirement by December 24, 2025.
• Final voting results will be disclosed in a Current Report on Form 8-K within four business days after the 2025 Annual Meeting.
• Stockholders who intend to have a proposal considered for inclusion in proxy materials for the 2026 Annual Meeting must submit it by May 8, 2026.

Key Dates

Recommendation

The company is taking necessary steps, such as proposing a reverse stock split, to maintain its Nasdaq listing, which is crucial for liquidity and access to capital. The expansion of the equity incentive plan is also a standard practice to attract and retain talent in a competitive industry. However, the underlying financial performance, characterized by consistent losses and a sub-$1.00 share price necessitating the reverse split, along with the potential for significant dilution from the expanded equity plan, presents considerable risks. A 'Hold' recommendation reflects the balance between these necessary strategic moves and the ongoing financial headwinds and dilution concerns. Investors should monitor the effectiveness of the reverse split in maintaining Nasdaq compliance and the company's progress in achieving profitability or significant milestones.

Keywords

Silo Pharma, Reverse Stock Split, Nasdaq Compliance, Equity Incentive Plan, Shareholder Meeting, Corporate Governance, Executive Compensation, Stock Dilution, Biopharmaceutical, Psychedelics